Browse by Audience
Skip to content
Papers of the Week
Systemic administration of NIS-lncRNA antisense oligonucleotide alleviates neuropathic pain.
Authors
Berkmana T, Li X, Liang Y, Korban A, Bekker A, Tao YXAbstract
The antisense oligonucleotide (ASO) is an FDA-approved strategy in the treatment of neurological diseases. We have shown the viability of using intrathecal ASO to suppress nerve injury-specific long noncoding RNA (NIS-lncRNA) in dorsal root ganglion (DRG), resulting in a stable and long-lasting antinociceptive effect on NP. This study examined whether systemic administration of NIS-lncRNA ASO relieved the chronic constriction injury (CCI)-induced nociceptive hypersensitivity.